FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D	.C. 20549
---------------	-----------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number: 3235-0287									
Estimated average I	Estimated average burden								
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 Instruction 1(b).

Name and Address of Reporting Person*     Dagnon Terry					2. Issuer Name <b>and</b> Ticker or Trading Symbol Outlook Therapeutics, Inc. [ OTLK ]							(Ched	ck all app Direc	ationship of Reporti k all applicable) Director Officer (give title		son(s) to Is 10% Ov Other (s	wner		
(Last) (First) (Middle) C/O OUTLOOK THERAPEUTICS, INC. 485 ROUTE 1 SOUTH, BUILDING F, SUITE 320					3. Date of Earliest Transaction (Month/Day/Year) 12/06/2021							X	below			below)			
(Street) ISELIN (City)	NJ (Sta		8830 (ip)		4. If <i>F</i>	4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Ind Line) X	vidual or Joint/Group Filing (Check Applicable  Form filed by One Reporting Person  Form filed by More than One Reporting  Person					
		Table	I - Nor	n-Deriva	tive S	Secui	rities	Acq	uired,	Dis	posed of	, or E	Benef	iciall	y Own	ed			
1. Title of Security (Instr. 3)  2. Transact Date (Month/Day					Execution Date,		3. Transaction Code (Instr. 8)  4. Securities Acquired Disposed Of (D) (Instr. 5)					5. Amount of Securities Beneficially Owned Following		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership			
					Code V		Amount (A) or (D)		or P	rice	Report Transa (Instr. 3	ction(s)			(Instr. 4)				
Common Stock 12/06/2					2021				P		25,201	A	A 5	\$1.38	8 1,163,058			D	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	vative Conversion Date Execution Date, irity or Exercise (Month/Day/Year) if any		on Date,	Transaction of Code (Instr. Deriv		ative rities ired osed . 3, 4	Expiration Date (Month/Day/Year)  Date Expiratio		te	7. Title and Amount of Securities Underlying Derivative Security (Ins 3 and 4)  Amou or Numb of Title Share		Set (In	Price of erivative ecurity estr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	y	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		

**Explanation of Responses:** 

Remarks:

/s/ Lawrence Kenyon, Attorney-in-Fact

12/06/2021

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.